Lumona FT 5 mg (Flash Tablet)
Medicine Details
| Category | Details |
|---|---|
| Generic | Montelukast sodium |
| Company | Eskayef pharmaceuticals ltd |
| Also available as |
Title
Lumona FT 5 mg Flash Tablet
Categories
- Medicine
- Healthcare
- Pharmaceutical
Description
Lumona FT is a selective and orally active leukotriene receptor antagonist used for prophylaxis and chronic treatment of asthma, acute prevention of Exercise-Induced Bronchoconstriction (EIB), and relief of symptoms of Allergic Rhinitis (AR). It is available in different dosages for adults, adolescents, and pediatric patients. Lumona FT exhibits a pharmacological mode of action by inhibiting the cysteinyl leukotriene receptor, which is correlated with the pathophysiology of asthma and allergic rhinitis. The product has specific dosage recommendations for patients with hepatic or renal insufficiency as well as for elderly use. It has been administered with other therapies routinely used in the prophylaxis and chronic treatment of asthma with no apparent increase in adverse reactions. The common side effects of Lumona FT include diarrhea, fever, headache, nausea, vomiting, and skin reactions. It is contraindicated in patients who are hypersensitive to any of its components. Additionally, caution should be exercised when using Lumona FT during pregnancy and lactation. The medicine should not be used in the reversal of bronchospasm in acute asthma attacks, and appropriate rescue medication should be available for such situations. Lumona FT should not be used as monotherapy for the treatment and management of exercise-induced bronchospasm. The average duration of its effect is 24 hours. It should be stored in a cool and dry place below 30°C, protected from light and moisture, and kept out of reach of children.
DosageOptions
- Montelukast 10 mg tablet once daily for adults and adolescents 15 years of age and older
- Montelukast 5 mg tablet once daily for pediatric patients 6 to 14 years of age
- Montelukast 4 mg tablet once daily for pediatric patients 2 to 5 years of age
- Montelukast 4 mg oral granules once daily for pediatric patients 6 months to 5 years of age
Indications
- Prophylaxis and chronic treatment of asthma
- Acute prevention of Exercise-Induced Bronchoconstriction (EIB)
- Relief of symptoms of Allergic Rhinitis (AR): Seasonal & Perennial Allergic Rhinitis
Pharmacology
Montelukast is a selective and orally active leukotriene receptor antagonist that inhibits the cysteinyl leukotriene receptor (CysLT1), which has been correlated with the pathophysiology of asthma and allergic rhinitis.
InteractionStudies
No clinically important effects on the pharmacokinetics of several drugs including theophylline, prednisone, oral contraceptives, terfenadine, digoxin, and warfarin when co-administered with Lumona FT.
SafeForElderly
The pharmacokinetic profile and the oral bioavailability of Lumona FT are similar in elderly and younger adults. The plasma half-life of Lumona FT is slightly longer in the elderly.
Contraindications
Lumona FT is contraindicated in patients who are hypersensitive to any component of this product.
CommonSideEffects
- Diarrhoea
- Fever
- Gastrointestinal discomfort
- Headache
- Nausea
- Vomiting
- Skin reactions
- Upper respiratory tract infection
UncommonSideEffects
- Akathisia
- Anxiety
- Arthralgia
- Asthenia
- Abnormal behavior
- Depression
- Dizziness
- Drowsiness
- Dry mouth
- Haemorrhage
- Irritability
- Malaise
- Muscle complaints
- Oedema
- Seizure
- Abnormal sensation
- Sleep disorders
RareSideEffects
- Angioedema
- Impaired concentration
- Disorientation
- Eosinophilic granulomatosis with polyangiitis
- Erythema nodosum
- Hallucination
- Hepatic disorders
- Memory loss
- Palpitations
- Pulmonary eosinophilia
- Suicidal tendencies
- Tremor
PregnancyWarnings
Use of Lumona FT during pregnancy should be avoided unless clearly needed. Caution should be exercised when Lumona FT is given to a nursing mother.
Precautions
Lumona FT is not indicated for use in the reversal of bronchospasm in acute asthma attacks. Patients should have appropriate rescue medication available. It should not be abruptly substituted for inhaled or oral corticosteroids. It should not be used as monotherapy for the treatment and management of exercise-induced bronchospasm.
OverdoseEffects
Adverse experiences in overdosage reports included abdominal pain, somnolence, thirst, headache, vomiting, and psychomotor hyperactivity. Usual supportive measures should be employed in case of overdose.
TherapeuticClass
Leukotriene receptor antagonists
StorageConditions
Store in a cool and dry place below 30°C, protect from light and moisture. Keep out of reach of children.
MolecularFormula
C35H36ClNO3S
ChemicalStructureImageURL
https://medex.com.bd/storage/res/g-res-768-montelukast-sodium-chemical-structure-drK1lRHjspWQ7613gJoZ.svg
FAQs
- What is Lumona FT 5 mg Flash Tablet?
- What is Lumona FT 5 mg Flash Tablet used for?
- How soon can the effect of Lumona FT 5 mg Flash Tablet be observed?
- How long does the effect of Lumona FT 5 mg Flash Tablet last?
- Should I use Lumona FT 5 mg Flash Tablet empty stomach?
- What if I miss a dose of Lumona FT 5 mg Flash Tablet?
- Are there any pregnancy warnings for Lumona FT 5 mg Flash Tablet?
- General Instructions: Take Lumona FT 5 mg Flash Tablet exactly as prescribed by your doctor. Do not change your Lumona FT 5 mg Flash Tablet dose or stop using asthma medication without your doctor's advice. Lumona FT 5 mg Flash Tablet is not a fast-acting rescue medicine for asthma attacks. Seek medical attention if your breathing problems get worse quickly, or if you think your medications are not working. Avoid situations or activities that may trigger an asthma attack. Talk to your doctor before using Lumona FT 5 mg Flash Tablet if you're pregnant or breastfeeding. They can help you decide if it's the right choice for you.